Published in JAMA on July 04, 2001
A copy number variation morbidity map of developmental delay. Nat Genet (2011) 9.58
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
Practical issues in imputation-based association mapping. PLoS Genet (2008) 6.76
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest (2007) 5.38
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Glutathione-S-transferase M1, obesity, statins, and autonomic effects of particles: gene-by-drug-by-environment interaction. Am J Respir Crit Care Med (2005) 2.64
Relative burden of large CNVs on a range of neurodevelopmental phenotypes. PLoS Genet (2011) 2.46
Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry (2007) 2.44
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med (2011) 2.40
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr (2006) 2.07
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet (2009) 1.92
Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ (2005) 1.90
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet (2008) 1.89
Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther (2013) 1.69
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res (2002) 1.66
Tracing sub-structure in the European American population with PCA-informative markers. PLoS Genet (2008) 1.56
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Potential therapeutic role for statins in respiratory disease. Thorax (2006) 1.49
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med (2003) 1.47
Medium-term exposure to traffic-related air pollution and markers of inflammation and endothelial function. Environ Health Perspect (2011) 1.45
Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events. Circ Cardiovasc Genet (2014) 1.44
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des (2012) 1.42
C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation (2003) 1.40
Association of statin use with cognitive decline in elderly African Americans. Neurology (2007) 1.34
Anti-inflammatory therapies for cardiovascular disease. Eur Heart J (2014) 1.28
Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag (2006) 1.23
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet (2008) 1.21
Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 1.21
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res (2016) 1.20
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.20
Residential traffic exposure, pulse pressure, and C-reactive protein: consistency and contrast among exposure characterization methods. Environ Health Perspect (2010) 1.19
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol (2008) 1.14
Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis (2012) 1.13
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One (2009) 1.10
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart (2004) 1.08
DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr (2009) 1.06
C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol (2009) 1.05
Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One (2010) 1.05
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg (2004) 1.03
Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev (2003) 1.03
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol (2010) 1.02
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J (2011) 0.99
Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study. J Am Geriatr Soc (2011) 0.98
Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc (2012) 0.97
Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol (2010) 0.96
Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity. Diabetes Metab J (2011) 0.95
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med (2005) 0.94
Strength Training for Arthritis Trial (START): design and rationale. BMC Musculoskelet Disord (2013) 0.93
Quantile-specific penetrance of genes affecting lipoproteins, adiposity and height. PLoS One (2012) 0.93
Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep (2009) 0.93
Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels (2005) 0.91
The controversy over the association between statins use and progression of age-related macular degeneration: a mini review. Clin Ophthalmol (2010) 0.91
Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med (2013) 0.91
High-Sensitivity C-Reactive Protein Is Associated With Incident Type 2 Diabetes Among African Americans: The Jackson Heart Study. Diabetes Care (2015) 0.90
Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag (2005) 0.89
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res (2012) 0.89
Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin Proc (2010) 0.89
Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol (2010) 0.89
Acute myocardial infarction leads to acceleration of atherosclerosis. Atherosclerosis (2013) 0.88
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation (2007) 0.88
Beneficial effects of cardiac rehabilitation and exercise after percutaneous coronary intervention on hsCRP and inflammatory cytokines in CAD patients. Pflugers Arch (2007) 0.88
Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer (2012) 0.87
Significant association between Helicobacter pylori infection and serum C-reactive protein. Int J Med Sci (2008) 0.87
Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders. Pulm Med (2012) 0.87
Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. Lipids (2008) 0.87
The Effect of Sodium Tanshinone IIA Sulfate and Simvastatin on Elevated Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease: A Study Protocol for a Randomized Controlled Trial. Evid Based Complement Alternat Med (2013) 0.87
IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol (2014) 0.86
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther (2005) 0.86
Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke (2011) 0.86
A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. J Lipid Res (2009) 0.86
Pravastatin suppresses matrix metalloproteinase expression and activity in human articular chondrocytes stimulated by interleukin-1β. J Orthop Traumatol (2012) 0.86
Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res (2012) 0.86
Implications of genetic polymorphisms in inflammation-induced atherosclerosis. Open Cardiovasc Med J (2010) 0.86
Cardiogenic shock in ACS. Part 1: prediction, presentation and medical therapy. Nat Rev Cardiol (2011) 0.86
Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J Membr Biol (2005) 0.85
Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation. Clin Exp Immunol (2006) 0.85
Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese population: a cross-sectional study. BMC Nephrol (2013) 0.85
Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. Chest (2008) 0.85
The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep (2011) 0.84
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Tex Heart Inst J (2009) 0.84
Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects. Vasc Health Risk Manag (2009) 0.84
The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol (2007) 0.84
Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels (2006) 0.84
ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis. Circulation (2014) 0.83
Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc (2009) 0.83
Association between C-reactive protein and QTc interval in middle-aged men and women. Eur J Epidemiol (2006) 0.83
Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. Pediatr Nephrol (2006) 0.83
C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. J Thorac Dis (2013) 0.83
Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal (2013) 0.83
An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease. Biomark Insights (2008) 0.83
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine (2015) 0.82
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr (2001) 5.67
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem (2001) 3.17
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem (2001) 2.81
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 2.34
Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest (1996) 2.31
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation (1999) 1.96
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int (2006) 1.84
Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia (2007) 1.80
Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem (2000) 1.74
Soluble P-selectin and the risk of future cardiovascular events. Circulation (2001) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
False increase of cardiac troponin I with heterophilic antibodies. Clin Chem (1998) 1.63
Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care (2001) 1.63
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol (2000) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Height and incidence of cardiovascular disease in male physicians. Circulation (1993) 1.62
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost (2006) 1.61
Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet (1999) 1.61
Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem (2000) 1.58
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation (1999) 1.57
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol (1999) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem (2000) 1.52
Surgical management of carcinoid heart disease. Ann Thorac Surg (1991) 1.50
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation (2001) 1.50
Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med (1999) 1.47
C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost (2004) 1.46
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost (2001) 1.45
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol (2001) 1.44
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J (2001) 1.44
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol (1995) 1.44
Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem (1998) 1.43
Factor V Leiden and recurrent venous thromboembolism. Thromb Haemost (1996) 1.39
Evaluation of the APEC analyzer for whole blood glucose. Testing in a pediatric setting. Am J Clin Pathol (1995) 1.39
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA (1996) 1.39
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol (2001) 1.38
Glycaemic control and diabetes care utilization in young adults with Type 1 diabetes. Diabet Med (2008) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med (2000) 1.33
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (1998) 1.32
Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab (2004) 1.31
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med (2001) 1.30
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Lipid levels and the risk of ischemic stroke in women. Neurology (2007) 1.23
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med (2007) 1.22
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol (1999) 1.22
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Migraine and biomarkers of cardiovascular disease in women. Cephalalgia (2007) 1.21
Trials of Hypertension Prevention, phase II. Structure and content of the weight loss and dietary sodium reduction interventions. Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol (1995) 1.19
Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther (1995) 1.17
Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet (2006) 1.14
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med (1997) 1.13
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation (2000) 1.13
Effect of vitamin supplementation to HIV-infected pregnant women on the micronutrient status of their infants. Eur J Clin Nutr (2005) 1.12
Beta 2-microglobulin and neopterin: predictive markers for human immunodeficiency virus type 1 infection in children? J Clin Microbiol (1990) 1.11
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation (1997) 1.11
Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis (2001) 1.11
Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control (1999) 1.08